{
  "docId": "019de075-3cec-7700-94db-076a5ce30d84",
  "docSlug": "8c2d629a90974743be7d15f16a23e50f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 52,
  "pageCount": 56,
  "prevPage": 51,
  "nextPage": 53,
  "slideType": "team_bio",
  "function": "cite_precedent",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide serves as a credibility transfer by showcasing the partner's team and achievements.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-3cec-7700-94db-076a5ce30d84/52",
  "deckHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84",
  "deckJsonHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84.json",
  "deckAnchorHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84#slide-52",
  "components": [
    {
      "bbox": {
        "h": 0.13,
        "w": 0.08,
        "x": 0.74,
        "y": 0.348
      },
      "kind": "image",
      "text": "Hussam Shaheen, SVP Biotherapeutics",
      "attrs": null,
      "subkind": "headshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38ec050f-827e-4a2e-9810-62960a845e4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.08,
        "x": 0.87,
        "y": 0.348
      },
      "kind": "image",
      "text": "Jason Oh, VP Biology",
      "attrs": null,
      "subkind": "headshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fd5bce6-72a1-4a30-a184-c81119dd1d42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.08,
        "x": 0.61,
        "y": 0.568
      },
      "kind": "image",
      "text": "Shawn Russell, VP CMC",
      "attrs": null,
      "subkind": "headshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ccf418f-3ed9-4dd3-beed-c7c6ba6efa13",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.08,
        "x": 0.61,
        "y": 0.348
      },
      "kind": "image",
      "text": "Evan Thompson, COO",
      "attrs": null,
      "subkind": "headshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8a98f5e-0029-44a0-b48d-978a12683fbe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.08,
        "x": 0.87,
        "y": 0.568
      },
      "kind": "image",
      "text": "Neta Batscha, VP Operations & Strategy",
      "attrs": null,
      "subkind": "headshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3929f33-7409-4c3d-89a3-716bf6940926",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.08,
        "x": 0.74,
        "y": 0.568
      },
      "kind": "image",
      "text": "Cyrus Stacey, VP Quality",
      "attrs": null,
      "subkind": "headshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d46ed4f3-0c49-41a1-b45b-71b827fd0508",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.55,
        "x": 0.02,
        "y": 0.195
      },
      "kind": "list",
      "text": "Paragon Therapeutics was founded in 2021 by Fairmount. 21 Professionals with deep expertise in antibody engineering and drug development from across the industry. Capabilities augmented by facilities and scientists at FairJourney Biologics and contract research organizations across the globe. 12 Programs currently in development with lead program on track to enter clinical trials in 3Q23, less than 2 years from ideation. Launched first spinout, Apogee Therapeutics, in 2022, which went public in July 2023 in a $345M IPO.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ab503be-7093-4b5d-92bd-cbbb99beb509",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Spyre antibodies were developed by our partners at Paragon",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d04603dd-14e9-41e4-b88f-bf7a07f3db78",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "credibility-transfer",
      "slug": null,
      "matchId": "e4f78b45-81bd-4c83-a26d-385126fc314b",
      "evidence": "Leveraging partner reputation to validate internal development",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 56,
      "from": 45,
      "beatId": "712c62dc-223b-4b2c-ba9f-cd5c102db383",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document calls for action, outlining the company's plans and milestones",
      "position": 5,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}